← Research library / Growth hormone axis
Ipamorelin remains in FDA Category 2 and is not eligible for compounding. It was not among the seven compounds reviewed at the July 2026 advisory committee meeting. It is also one of the most heavily advertised peptides in the United States, which tells you something about how much of that advertising is compliant.
Ipamorelin is a pentapeptide that stimulates growth hormone release through the ghrelin receptor, a different route from GHRH analogs like sermorelin. Older compounds in this class, particularly GHRP-6 and hexarelin, also raised cortisol, prolactin and appetite. Ipamorelin was designed to be more selective, which is a genuine pharmacological improvement.
Ipamorelin reliably raises growth hormone in short-term human studies. That much is established. What is missing is the next step: controlled trials showing that the biomarker change produces meaningful outcomes in body composition, recovery or anything else people buy it for.
FDA cited concerns including potential immunogenicity and the absence of rigorous human safety data when it restricted this class. Those concerns have not been resolved by new evidence.
The logic is sound on paper. CJC-1295 acts on the GHRH receptor, ipamorelin on the ghrelin receptor, and the combination produces a larger release than either alone. It is the most advertised pairing in the category. Both components are FDA restricted, so the combination is not available regardless of what price you were quoted.
Full library · Safety and sourcing · Reconstitution calculator · Compound index
Regulatory status current as of the page date. This area is changing quickly and this page is reviewed monthly. [set review reminder]